Technology area: Biotechnology & Pharmaceuticals
15 pending office actions • 14 clients • 15 examiners • 12 art units • 0 of 15 (0%) have an AI response strategy ready
Juniv LLP has 17 pending office actions in Biotechnology & Pharmaceuticals and 268 career applications. Its resolved allowance rate is 77.08%, and the average office actions per allowance is 3.32. These figures show an active portfolio with both current examination work and a recorded history of resolved applications.
The allowance rate applies to resolved matters, whereas pending office actions identify work still in progress. The office-action average suggests that matters reaching allowance have typically required more than one examination interaction. Practitioners can use the profile to frame response planning around iterative claim development, with particular attention to written support, enablement, and distinctions over technically relevant prior art.
Based on the USPTO statutory response window for each pending office action. 9 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 9 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (7%) |
| §103 only | 5 (33%) |
| Double-patenting + other | 7 (47%) |
| Multi-statute (no §101) | 2 (13%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CANDELARIA, JULIANA IRENE | 1 | 0.0% | +0.0% |
| MOU, LIYUAN | 1 | 43.8% | +59.9% |
| LEE, ANDREW P | 1 | 48.5% | +22.8% |
| MOEHLMAN, ANDREW TERRY | 1 | 67.0% | +59.7% |
| HOWELL, THEODORE R | 1 | 66.9% | +25.1% |
| HUI, SAN MING R | 1 | 59.6% | +20.0% |
| MCKNIGHT, CIARA A | 1 | 61.5% | +40.3% |
| BRAUN, MADELINE E | 1 | 68.4% | +25.3% |
| SAEED, ALI S | 1 | 31.6% | +33.8% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.4% | +24.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18547018 | CRYPTOPHYCIN COMPOUNDS AND CONJUGATES THEREOF | BRAUN, MADELINE E | 5d |
| 18510944 | LFA-1 ANTAGONISTS FOR TREATING INFLAMMATORY BOWEL DIESEASE | HOWELL, THEODORE R | 84d |
| 18908061 | METHOD FOR TREATING TUMOR USING IMMUNE CELL | CANDELARIA, JULIANA IRENE | — |
| 18649917 | ENGINEERED ALPHA-GALACTOSIDASE A (A-GAL A) PEPTIDES AND FUNCTIONAL VARIANTS THEREOF AND ASSOCIATED METHODS OF TREATING FABRY DISEASE | MOEHLMAN, ANDREW TERRY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18547018 | CRYPTOPHYCIN COMPOUNDS AND CONJUGATES THEREOF | BRAUN, MADELINE E | 5d |
| 18245125 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | WHITE, DAWANNA SHAR-DAY | 12d |
| 18550967 | FUSION PROTEINS COMPRISING GG REPEAT SEQUENCES | MCKNIGHT, CIARA A | 13d |
| 18510944 | LFA-1 ANTAGONISTS FOR TREATING INFLAMMATORY BOWEL DIESEASE | HOWELL, THEODORE R | 84d |
| 18813917 | CRYSTALLINE FORMS OF A DEOXYCYTIDINE KINASE INHIBITOR AND USES THEREOF | MOU, LIYUAN | — |
| 18732637 | ASCORBIC ACID AND QUINONE COMPOUNDS FOR TREATING CHAGAS DISEASE | LEE, ANDREW P | — |
| 18649917 | ENGINEERED ALPHA-GALACTOSIDASE A (A-GAL A) PEPTIDES AND FUNCTIONAL VARIANTS THEREOF AND ASSOCIATED METHODS OF TREATING FABRY DISEASE | MOEHLMAN, ANDREW TERRY | — |
| 18552482 | KRAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | HUI, SAN MING R | — |
| Art Unit | Apps |
|---|---|
| 1628 | 3 |
| 1627 | 2 |
| 1634 | 1 |
| 1691 | 1 |
| 1655 | 1 |
| 1656 | 1 |
| 1624 | 1 |
| 1616 | 1 |
| 1644 | 1 |
| 1622 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18908061 | METHOD FOR TREATING TUMOR USING IMMUNE CELL | Carsgen Therapeutics Co., Ltd. | CANDELARIA, JULIANA IRENE | 1634 | §102§103§112DP | Non-Final OA | — | Pending | Oct 07, 2024 |
| 18813917 | CRYSTALLINE FORMS OF A DEOXYCYTIDINE KINASE INHIBITOR AND USES THEREOF | Trethera Corporation | MOU, LIYUAN | 1628 | §103§112DP | Non-Final OA | — | Pending | Aug 23, 2024 |
| 18732637 | ASCORBIC ACID AND QUINONE COMPOUNDS FOR TREATING CHAGAS DISEASE | Ic-Medtech Corp. | LEE, ANDREW P | 1691 | §103 | Non-Final OA | — | Pending | Jun 04, 2024 |
| 18649917 | ENGINEERED ALPHA-GALACTOSIDASE A (A-GAL A) PEPTIDES AND FUNCTIONAL VARIANTS THEREOF AND ASSOCIATED METHODS OF TREATING FABRY DISEASE | Sichuan Real&Best Biotech Co., Ltd. | MOEHLMAN, ANDREW TERRY | 1655 | §101§102§103§112 | Non-Final OA | — | Pending | Apr 29, 2024 |
| 18510944 | LFA-1 ANTAGONISTS FOR TREATING INFLAMMATORY BOWEL DIESEASE | Vivavision Biotech, Inc. | HOWELL, THEODORE R | 1628 | §102§112 | Non-Final OA | 84d | Pending | Nov 16, 2023 |
| 18552482 | KRAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | HUI, SAN MING R | 1627 | §103 | Non-Final OA | — | Pending | Sep 26, 2023 |
| 18550967 | FUSION PROTEINS COMPRISING GG REPEAT SEQUENCES | Numaferm GmbH | MCKNIGHT, CIARA A | 1656 | §102DP | Final Rejection | 13d | Pending | Sep 17, 2023 |
| 18547018 | CRYPTOPHYCIN COMPOUNDS AND CONJUGATES THEREOF | Universitat Bielefeld | BRAUN, MADELINE E | 1624 | §102§103§112 | Non-Final OA | 5d | Pending | Aug 18, 2023 |
| 18253455 | DRY POWDER ANTIVIRAL COMPOSITIONS AND THEIR USE FOR TREATING VIRAL INFECTION | Nano Pharmasolutions, Inc. | SAEED, ALI S | 1616 | §102§103DP | Final Rejection | — | Pending | May 18, 2023 |
| 18245125 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | WHITE, DAWANNA SHAR-DAY | 1627 | §103DP | Non-Final OA | 12d | Pending | Mar 13, 2023 |
| 18174565 | COMPOSITIONS AND METHODS OF CELLULAR IMMUNOTHERAPY | Crage Medical Co., Limited | BELYAVSKYI, MICHAIL A | 1644 | §103 | Final Rejection | 393d overdue | Pending | Feb 24, 2023 |
| 17999843 | BIARYLSULFONAMIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE FOR TREATING FIBROTIC LUNG DISEASE | NovoMedix, LLC | WELLS, LAUREN QUINLAN | 1622 | §103DP | Non-Final OA | 13d | Pending | Nov 23, 2022 |
| 17634963 | GENETICALLY ENGINEERED CELLS AND USES THEREOF | Cure Genetics Co., Limited | DIBRINO, MARIANNE | 1641 | §102§112DPOther | Final Rejection | 70d overdue | Pending | Nov 09, 2022 |
| 17963504 | THERAPEUTIC COMBINATIONS OF ORALLY ADMINISTERED PACLITAXEL AND A P-gp INHIBITOR FOR THE TREATMENT OF ANGIOSARCOMA | Health Hope Pharma Hk Limited | BARSKY, JARED | 1628 | §103 | Final Rejection | 87d overdue | Pending | Oct 11, 2022 |
| 17623481 | CELL FOR RESISTING TRANSPLANT REACTION AND METHOD | Carsgen Life Sciences Co., Ltd. | TRAN, KHOA NHAT | 1632 | §103 | Final Rejection | 4d overdue | Pending | Dec 28, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial77.1% of resolved applications prosecuted by Juniv LLP were allowed, across 268 applications in USPTO records.
3.32 office actions per allowed application on average.
15 pending office actions as of October 2026, for 14 clients, before 15 examiners in 12 art units.
